SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer.

Sodium calcium edetate + tobramycin is under clinical development by Respirion Pharmaceuticals and currently in Phase II for Cystic Fibrosis.

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Anti-PD-1/VEGF BsAb is under clinical development by 3SBio and currently in Phase II for Gynecological Cancer.

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL).

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

PrimePro is under clinical development by Thomas Advanced Medical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

GIP/GLP-1 Coagonist III is under clinical development by Eli Lilly and Co and currently in Phase I for Cardiometabolic Disease.

QTX-3046 is under development for the treatment of solid tumor, colorectal, pancreatic, endometrial cancer and lung cancer. It is administered through oral route. The drug candidate acts by targeting ...